Consequently, PD-1/PD-L1/PD-L2 inhibitors—known as checkpoint inhibitors—have shown substantial efficacy in treating Hodgkin’s lymphoma, although their impact in AML treatment was considerably lower [109,110]. The gene discussed is CD274; the disease is acute myeloid leukemia.